Restrictive or obstructive pulmonary disease
History of clinically severe lung disease, asthma, or chronic obstructive pulmonary disease (COPD) requiring emergency management and/or hospitalization in the last year
Pulmonary disease requiring chronic medical therapy, unrelated to underlying cancer
Severe chronic obstructive pulmonary disease (COPD) defined as disease requiring an inpatient stay for respiratory deterioration within the past 3 months
Pulmonary: no requirement for supplemental oxygen and no evidence of moderate-severe chronic obstructive pulmonary disease (COPD) by pulmonary function tests (PFTs)
Uncontrolled medical conditions including diabetes, heart failure, chronic obstructive pulmonary disease (COPD), ulcerative colitis, or Crohn’s disease
If they have New York Heart Association (NYHA) class 3 or 4: myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contraindicates treatment with sEphB4HSA or places the patient at undue risk for treatment related complications
Forced expiratory volume in 1 second (FEV1) >= 2.0 liters or >= 75% of predicted for height and age; (pulmonary function tests (PFTs) are required for patients over 50 or with significant pulmonary or smoking history defined as > 20 pack years or history of chronic obstructive pulmonary disease [COPD]/emphysema)
Pulmonary disease which, in the opinion of the investigator, may impair the patient's respiratory tolerance to moderate pulmonary fluid overload (e.g., interstitial lung disease, severe chronic obstructive pulmonary disease)
New York Heart Association class 3 or 4 heart failure; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis, or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contraindicates treatment with sEPHB4-HSA or places the patient at undue risk for treatment related complications
Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis
Chronic medical illness including diabetes with the use of insulin, hemoglobin A1c > 7 (study physician discretion), heart disease diagnosed by angiogram, chronic obstructive pulmonary disease (COPD) diagnosed by pulmonary function testing and requiring an oxygen supply
History of clinically significant chronic obstructive pulmonary disease (COPD), asthma, or other chronic lung disease.
Known severe chronic obstructive pulmonary disease or asthma
Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, or pulmonary fibrosis
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Patients who have major medical problems such as severe cardiac, pulmonary (COPD requiring constant oxygen), or non-healing ulceration.
Significant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function test (PFT)’s indicating an forced expiratory volume in 1 second (FEV1) less than 50% or a carbon monoxide diffusing capability test (DLCO) less than 40% predicted for age\r\n* Note: Patients who have shortness of breath with minimal exertion or who are at risk for pulmonary disease will undergo pulmonary function testing and will not be eligible if their FEV1 is < 50% of expected
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Patients with pre-existing uncontrolled pulmonary disease will be excluded; uncontrolled refers to patients having had at least one hospitalization due to pulmonary disease (for example, asthma, chronic obstructive pulmonary disease) within the 6 months prior to enrollment in the study; patients with previous history of pneumonitis will be excluded
Has known history of, or any evidence of active, non-infectious pneumonitis that required steroids (steroid treatment of chronic obstructive pulmonary disease [COPD] or asthma allowed)
Has New York Heart Association (NYHA) class 3 or 4, myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contraindicates treatment with sEphB4HSA or pembrolizumab (MK-3475) or places the patient at undue risk for treatment related complications
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
Significant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function tests (PFTs) indicating a forced expiratory volume in one second (FEV1) less than 50% or a diffusion capacity of carbon monoxide (DLCO) less than 40% predicted for age
Pulmonary disease: severe chronic obstructive lung disease, or symptomatic restrictive lung disease
Serious medical conditions (congestive heart failure [CHF], angina, diabetes mellitus type 1, chronic obstructive pulmonary disease [COPD], bleeding diathesis)
Criteria 7 Known chronic obstructive pulmonary disease (COPD) with a FEV1 < 50% of predicted normal
Chronic Obstructive Pulmonary Disease, defined as being associated with a hospitalization for pneumonia or respiratory decompensation within 12 months of diagnosis; this does not include obstruction from tumor
If they have New York Heart Association (NYHA) class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months; or any other intercurrent medical condition that contraindicates treatment with sEphB4-HSA or places the patient at undue risk for treatment related complications
Severe chronic obstructive pulmonary disease (COPD) with hypoxemia
History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary disease requiring systemic steroid therapy, oxygen, or hospitalization
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, and pulmonary fibrosis
Severe chronic obstructive pulmonary disease (COPD) requiring > 3 hospitalizations in the past year
History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction
History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume [FEV] > 60% of predicted for height and age required in patients with prolonged smoking history or symptoms of respiratory dysfunction)
Severe chronic obstructive pulmonary disease requiring oxygen supplementation
History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume of the lung in 1 second [FEV1] > 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or signs, symptoms, or history of respiratory dysfunction)
Patients who require chronic oxygen therapy for chronic obstructive pulmonary disease or pleural effusions (malignant or benign)
History of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in one second [FEV1] > 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction
Significant chronic obstructive pulmonary disease (COPD) or other chronic pulmonary restrictive disease with pulmonary function tests (PFTs) indicating an forced expiratory volume in 1 second (FEV1) less than 50% or a diffusion capacity of the lung for carbon monoxide (DLCO) less than 40% predicted for age; Note: patients who have shortness of breath with minimal exertion or who are at risk for pulmonary disease (e.g., chronic smokers) will undergo pulmonary function testing and will not be eligible if their FEV1 is < 50% of expected
Clinically significant lung disease including known history or evidence of interstitial lung disease or chronic obstructive pulmonary disease (COPD) that requires oxygen therapy
Presentation of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease
Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. COPD requiring chronic oral steroid therapy
Evidence of pulmonary insufficiency or clinically evident chronic obstructive pulmonary disease
Active and ongoing steroid use, except for non-systemically absorbed treatments (such as inhaled or topical steroid therapy for asthma, chronic obstructive pulmonary disease [COPD], allergic rhinitis)
Known chronic obstructive pulmonary disease (COPD) OR moderate or severe persistent asthma within the past 2 years
Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
History of other pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in 1 second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
Subjects with a history of interstitial lung disease or lung disease that has required intubation in the past (i.e. such as asthma or chronic obstructive pulmonary disease [COPD]); patients requiring continuous supplemental oxygen are excluded
Any history of symptomatic pulmonary compromise, such as chronic obstructive pulmonary disease
Patients with significant impairment of pulmonary function on account of chronic bronchitis, emphysema or chronic obstructive pulmonary disease (COPD) which has resulted in impairment of vital capacity of forced expiratory volume in one second (FEV1) to less than 75% of predicted normal values
Concurrent major medical conditions, such as uncontrolled hypertension, diabetes mellitus, ischemic heart disease, chronic obstructive pulmonary disease, autoimmune disease, adrenal insufficiency, or prior allogeneic organ transplant requiring chronic immunosuppressive therapy, including systemic glucocorticoid treatment or replacement therapy
Severe hyperactive airway disease (chronic obstructive pulmonary disease, asthma)
Concomitant corticosteroid use for systemic or topical treatment of skin disease is not allowed except a dose of steroid of no more than 20 mg of prednisone or its equivalence is allowed for asthma, chronic obstructive pulmonary disease (COPD), or inflammatory bowel disease (IBD); stable use of topical corticosteroids of mid-potency will be allowed for patients with erythroderma-Sezary syndrome (T4) and tumor stage (T3) with intense pruritus
Severe chronic obstructive or other pulmonary disease with hypoxemia
Evidence of chronic obstructive pulmonary disease
Patients with significant impairment of pulmonary function on account of chronic bronchitis or chronic obstructive pulmonary disease (COPD) which has resulted in impairment of vital capacity of forced expiratory volume in one second (FEV1) to less than 75% of predicted normal values
Participants with diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months, or any other intercurrent medical condition that contraindicates treatment with sEphB4-HSA or places the participant at undue risk for treatment related complications
Severe or debilitating pulmonary disease (dyspnea at rest, significant shortness of breath, chronic obstructive pulmonary disease [COPD])
Asthma or chronic obstructive pulmonary disease (COPD) requiring daily medication.
Inflammatory lung disease including moderate and severe asthma and chronic obstructive pulmonary disease (COPD) requiring chronic medical therapy.
Patients with severe cardiac disease including symptomatic congestive heart failure, unstable angina, or have experience an acute myocardial infarction within the past 6 months; please note: patients with chronic obstructive pulmonary disease (COPD) are not excluded
History of other pulmonary disease such as emphysema or chronic obstructive pulmonary disease, (forced expiratory volume in one second [FEV1] < 60% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with prolonged smoking history or symptoms of respiratory dysfunction
Known moderate to severe chronic obstructive pulmonary disease (COPD), interstitial lung disease, pulmonary fibrosis, and pulmonary arterial hypotension.
Chronic steroid or immunosuppressive therapy (except for low dose corticosteroids for chronic obstructive pulmonary disease [COPD] or topical steroids, which are allowed)
Known moderate to severe chronic obstructive pulmonary disease, interstitial lung disease, and pulmonary fibrosis
No history of pulmonary disease such as emphysema or chronic obstructive pulmonary disease (COPD), (forced expiratory volume in one second [FEV1] > 2L or >= 50% of predicted for height and age); pulmonary function tests (PFTs) are required in patients with significant pulmonary or smoking history
Patient has a history of significant cardiovascular, neurological, endocrine, gastrointestinal, respiratory, or inflammatory illness including recent myocardial infarction (within 6 months)or stroke; hypertension requiring >2 medications for adequate control; diabetes mellitus with >2 episodes of ketoacidosis in the preceding 12 months; or chronic obstructive pulmonary disease (COPD) requiring >2 hospitalizations in the preceding 12 months.
Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment.
Severe chronic obstructive pulmonary disease (COPD) by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) staging system
Subjects on supplemental oxygen or history of chronic obstructive pulmonary disease (COPD)
Severe chronic obstructive pulmonary disease (COPD) requiring oxygen dependence, as this is a contraindication of EMST
Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplemental oxygen
Active or symptomatic cardiopulmonary disease (myocardial infarction < 1 month, heart failure >= New York Heart Association [NYHA] II, atrial fibrillation with poor rate control, high grade atrioventricular [AV] block, obstructive valvular disease, chronic obstructive pulmonary disease [COPD])
Other causes of cachexia such as: liver disease (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] > 3 x normal levels); renal failure (creatinine > 1.5 mg/dL), untreated thyroid disease, class III-IV congestive heart failure (CHF), acquired immune deficiency syndrome (AIDS), other cancer diagnosed within the past 5 years other than non-melanoma skin cancer, severe chronic obstructive pulmonary disease (COPD) requiring use of home oxygen (O2)
History of severe chronic obstructive pulmonary disease (COPD) and resting oxygen saturation (SpO2) < 90%
Chronic obstructive pulmonary disease (COPD)
Chronic obstructive pulmonary disease (COPD) exacerbation at the time of study enrollment
Diagnosed with chronic obstructive pulmonary disease (COPD) oxygen dependent
Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within 30 days before registration
Has a serious cardiopulmonary medical condition (including cardiovascular disease, congestive heart failure [CHF], chronic obstructive pulmonary disease [COPD], restrictive lung disease, interstitial lung disease, asthma, acute or chronic bronchitis, cystic fibrosis, pneumonia, tuberculosis, pneumoconiosis, pulmonary hypertension, pulmonary embolism, pleural effusion, pneumothorax, obesity hyperventilation syndrome, neuromuscular lung disease)
Known history of chronic pulmonary disease
Physician-diagnosed chronic obstructive pulmonary disease (COPD)
Severe obstructive lung disease (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage III or IV, FEV1 < 30% predicted)
Patients with stage II chronic obstructive pulmonary disease (COPD) or worse, per Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification
Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease [COPD] requiring oxygen)
Critically ill or medically unstable and whose critical course during the observation period would be unpredictable (e.g., chronic obstructive pulmonary disease [COPD])
Ongoing acute or chronic pulmonary bronchospastic disease, including a history of chronic obstructive pulmonary disease or asthma, with an exacerbation within the past year
Pre-existing respiratory conditions:\r\n* Severe chronic obstructive pulmonary disease (including chronic bronchitis and/or emphysema)\r\n* Other respiratory or lung conditions, which would place the participant at risk\r\n* Presence of any other significant cardiac or pulmonary symptoms, such as moderate or severe dyspnea on exertion, orthopnea, or paroxysmal nocturnal dyspnea
Patients must have pulmonary function as defined below:\r\n* Abnormal pulmonary function test within 3 months of study entry\r\n* Prior radiation to the lungs\r\n* Prior surgical resection of lung tissue (i.e. wedge resection, lobectomy, or pneumonectomy)\r\n* Clinical diagnosis of chronic obstructive pulmonary disease (COPD) or emphysema\r\n* Ongoing oxygen use
Immune system disorders, pulmonary diseases (e.g., asthma within the prior 5 years, acute bronchitis within 1 year, chronic obstructive pulmonary disease [COPD], chronic bronchitis, and restrictive lung disease), clinically diagnosed kidney or liver diseases, or any other medical disorders that will increase the risk from bronchoscopy, affect biomarker data, or increase risk of an adverse effect from e-cig use; all subjects are screened by a pulmonologist obtaining a medical history and a physical examination (heart, lungs and oral cavity) to ensure no increased risk from bronchoscopy or e-cig use
recent history (past 3 months) of Chronic Obstructive Pulmonary Disease (COPD), cancer (any non-dermatologic), or uncontrolled diabetes mellitus
pre-existing clinically significant dysfunction of the heart or Chronic Obstructive Pulmonary Disease (COPD)